699852P

Avanti

3D-PHAD®

Monophosphoryl 3-Deacyl Lipid A (Synthetic) Pat No. 9,241,988, powder

Empirical Formula (Hill Notation):
C82H158N3O20P
CAS号:
分子量:
1537.11
NACRES:
NA.25
价格与库存信息目前不能提供

assay

>99% (HPLC)

form

powder

packaging

pkg of 1 × 1 mg (699852P-1mg)
pkg of 1 × 5 mg (699852P-5mg)

mfr. no.

Avanti Polar Lipids, 699852P

shipped in

dry ice

storage temp.

−20°C

SMILES string

OC@H(C@@H(COC@@H(C@@H1NC(CC@H(OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)OC@H(CO)C@@H(OP(O-)(O)=O)C@@H1OC(CC@H(OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)OC@H(O)C@@H2NC(CC@H(O)CCCCCCCCCCC)=O)C@@H2O.NH4+

General description

Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD®), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.

Application

3D-PHAD® has been used:
  • as a synthetic adjuvant for respiratory syncytial virus (RSV) vaccine
  • as a synthetic adjuvant to prepare hepatitis B virus (HBV) and virus-like particles (VLP)-based human papillomavirus (HPV) vaccines
  • in liposome preparation for the generation of army liposome formulation (ALF) for human immunodeficiency (HIV) gp140 antigen immunization studies in mice.

Biochem/physiol Actions

3-deacyl-phosphorylated hexa-acyl disaccharide (3D-PHAD®) is derived from monophosphoryl lipid A. It is amphiphilic and associates with the virosomal membranes.

Packaging

2 mL Amber Glass Crimp Cap Vial (699852P-1mg)
2 mL Amber Glass Crimp Cap Vial (699852P-5mg)

Other Notes

For R&D use only. Not for drug, household, or other uses.

Legal Information

3D-PHAD is a registered trademark of Avanti Polar Lipids, Inc.
PHAD is a registered trademark of Avanti Polar Lipids, Inc.

RIDADR

NONH for all modes of transport

Development of a virosomal RSV vaccine containing 3D-PHAD Adjuvant: formulation, composition, and long-term stability
Lederhofer J
Pharmaceutical Research, 35(9), 172-172 (2018)
Monica L Martin et al.
Malaria journal, 18(1), 377-377 (2019-11-30)
Indian-origin rhesus (InR) are preferred for research, but strict export restrictions continue to limit their use. Chinese-origin rhesus (ChR), although easier to procure, are genetically distinct from InR and differ in their immune response to infectious agents, such as the...
Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex
Beck Z, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society, 275, 1219-1219 (2018)
Immunogenicity of HPV and HBV vaccines: adjuvanticity of synthetic analogs of monophosphoryl lipid A combined with aluminum hydroxide
Taleghani N, et al.
Acta Pathologica, Microbiologica et Immunological Scandinavica, 127(3), 150-157 (2019)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

社交媒体

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

科研、开发、生产。

作为生命科学行业的全球领先供应商,我们致力于为科研、生物技术开发和生产,以及制药药物疗法开发和生产提供各类解决方案和服务。

© 2021年版权归德国达姆施塔特默克集团(Merck KGaA)及/或其附属公司所有。版权所有。

未经许可,严禁复制本网站上的任何资料。